These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24254131)

  • 1. Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.
    Brown K; LaBrie M; Coffin CS
    Curr HIV/AIDS Rep; 2013 Dec; 10(4):420-7. PubMed ID: 24254131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.
    Chastain CA; Naggie S
    Curr HIV/AIDS Rep; 2013 Dec; 10(4):408-19. PubMed ID: 24272069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
    Andersohn F; Claes AK; Kulp W; Mahlich J; Rockstroh JK
    BMC Infect Dis; 2016 Jan; 16():10. PubMed ID: 26753774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
    Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM;
    Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
    Kovari H; Russmann S; Ledergerber B; Müller D; Rotger M; Velli P; Cavassini M; Ambrosioni J; Bregenzer A; Stöckle M; Bernasconi E; Rauch A; Speck RF;
    PLoS One; 2015; 10(7):e0133879. PubMed ID: 26218843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
    Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
    Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
    Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
    Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C.
    Núnez M; Camino N; Ramos B; Berdún MA; Barreiro P; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Martín-Carbonero L; Romero M; García-Samaniego J; Soriano V
    Antivir Ther; 2005; 10(5):657-62. PubMed ID: 16152759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
    Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P
    Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.